Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
The growth of marrow fibroblasts from patients with myeloproliferative disorders (MPD) was investigated using platelet derived growth factor (PDGF) and human serum as mitogens in the presence of human plasma derived serum. The proliferation of fibroblasts in MPD patients was increased compared to normal individuals, especially in patients with chronic myelocytic leukaemia and essential thrombocythaemia. This increment of proliferation might be due to higher sensitivity of the fibroblasts to plasma derived serum than to PDGF, because the ratio of proliferation with PDGF to that without PDGF, when compared between patients and normals, remained unchanged. These results suggest that MPD fibroblasts are more sensitive to some factor(s) in plasma, and this fact could partially explain the pathogenesis of myelofibrosis in MPD patients.
Kimura
A
A
Department of Internal Medicine, Research Institute for Nuclear Medicine and Biology, Hiroshima University, Japan.
Katoh
O
O
Kuramoto
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000473:pathology*; D002455:Cell Division; D002478:Cells, Cultured; D005260:Female; D005347:Fibroblasts / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000473:pathology*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology*
D010982:Platelet-Derived Growth Factor